The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Open accessAbstract
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified by PSMA PET imaging. Promising results with PSMA-targeted radiopharmaceutical therapy have already been obtained in early-phase studies using various combinations of targeting molecules and radiolabels. Definitive evidence of the safety and efficacy of [177 Lu]Lu-PSMA-617 in combination with standard-of-care has been demonstrated in patients with metastatic castration-resistant prostate cancer, whose disease had progressed after or during at least one taxane regimen and at least one novel androgen-axis drug. Preliminary data suggest that 177 Lu-PSMA-radioligand therapy (RLT) also has high potential in additional clinical situations. Hence, the radiopharmaceuticals [177 Lu]Lu-PSMA-617 and [177 Lu]Lu-PSMA-I&T are currently being evaluated in ongoing phase 3 trials. The purpose of this guideline is to assist nuclear medicine personnel, to select patients with highest potential to benefit from 177 Lu-PSMA-RLT, to perform the procedure in accordance with current best practice, and to prepare for possible side effects and their clinical management. We also provide expert advice, to identify those clinical situations which may justify the off-label use of [177 Lu]Lu-PSMA-617 or other emerging ligands on an individual patient basis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864
Self-citationScher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,654
Hofman, M. S., Violet, J., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T., Iravani, A., Kong, G., Ravi Kumar, A., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,174
Self-citationHofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00237-3 · Cited by 1,170
Self-citationRahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schäfers, M., Essler, M., Baum, R. P., Kulkarni, H. R., Schmidt, M., Drzezga, A., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183194 · Cited by 832
Self-citationBostwick, D. G., Pacelli, A., Blute, M., Roche, P., & Murphy, G. P. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980601)82:11<2256::aid-cncr22>3.0.co;2-s · Cited by 698
Kratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171397 · Cited by 636
Self-citationSweat, S. D., Pacelli, A., Murphy, G. P., & Bostwick, D. G. (1998) · Urology · doi:10.1016/s0090-4295(98)00278-7 · Cited by 607
Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues
Wright, G. L., Haley, C., Beckett, M. L., & Schellhammer, P. F. (1995) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/1078-1439(95)00002-y · Cited by 591
Baum, R. P., Kulkarni, H. R., Schuchardt, C., Singh, A., Wirtz, M., Wiessalla, S., Schottelius, M., Mueller, D., Klette, I., & Wester, H.-J. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168443 · Cited by 525
Self-citationViolet, J., Jackson, P., Ferdinandus, J., Sandhu, S., Akhurst, T., Iravani, A., Kong, G., Kumar, A. R., Thang, S. P., Eu, P., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.219352 · Cited by 504
Self-citationConstitutive and antibody-induced internalization of prostate-specific membrane antigen.
Liu, H., Rajasekaran, A. K., Moy, P., Xia, Y., Kim, S., Navarro, V., Rahmati, R., & Bander, N. H. (1998) · PubMed · Cited by 458
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
Paschalis, A., Sheehan, B., Riisnaes, R., Rodrigues, D. N., Gurel, B., Bertan, C., Ferreira, A., Lambros, M. B. K., Seed, G., Yuan, W., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.06.030 · Cited by 455
Self-citationTagawa, S. T., Milowsky, M. I., Morris, M., Vallabhajosula, S., Christos, P., Akhtar, N. H., Osborne, J., Goldsmith, S. J., Larson, S., Taskar, N. P., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0231 · Cited by 427
Self-citationMannweiler, S., Amersdorfer, P., Trajanoski, S., Terrett, J. A., King, D., & Mehes, G. (2009) · Pathology & Oncology Research · doi:10.1007/s12253-008-9104-2 · Cited by 384
Delker, A., Fendler, W. P., Kratochwil, C., Brunegraf, A., Gosewisch, A., Gildehaus, F. J., Tritschler, S., Stief, C. G., Kopka, K., Haberkorn, U., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3174-7 · Cited by 322
Self-citationHeck, M. M., Tauber, R., Schwaiger, S., Retz, M., D’Alessandria, C., Maurer, T., Gafita, A., Wester, H.-J., Gschwend, J. E., Weber, W. A., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.11.016 · Cited by 298
Self-citationAhmadzadehfar, H., Rahbar, K., Kürpig, S., Bögemann, M., Claesener, M., Eppard, E., Gärtner, F., Rogenhofer, S., Schäfers, M., & Essler, M. (2015) · EJNMMI Research · doi:10.1186/s13550-015-0114-2 · Cited by 293
Self-citationViolet, J., Sandhu, S., Iravani, A., Ferdinandus, J., Thang, S.-P., Kong, G., Kumar, A. R., Akhurst, T., Pattison, D., Beaulieu, A., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.236414 · Cited by 292
Self-citationGafita, A., Calais, J., Grogan, T. R., Hadaschik, B., Wang, H., Weber, M., Sandhu, S., Kratochwil, C., Esfandiari, R., Tauber, R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00274-6 · Cited by 271
Self-citationSjögreen Gleisner, K., Chouin, N., Gabina, P. M., Cicone, F., Gnesin, S., Stokke, C., Konijnenberg, M., Cremonesi, M., Verburg, F. A., Bernhardt, P., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05727-7 · Cited by 252
Self-citationRajasekaran, S. A., Anilkumar, G., Oshima, E., Bowie, J. U., Liu, H., Heston, W., Bander, N. H., & Rajasekaran, A. K. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-11-0731 · Cited by 226 · cited 2×
“Low tumor uptake of radiolabeled PSMA-ligands; also expressed as low tumor absorbed dose in patient-specific dosimetry, low SUVs in PSMA-PET, low tumor/liverratio, or low tumor/parotid-ratio in PSMA-SPECT/scintigraphy.”
BackgroundFendler, W. P., Reinhardt, S., Ilhan, H., Delker, A., Böning, G., Gildehaus, F. J., Stief, C., Bartenstein, P., Gratzke, C., Lehner, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.12240 · Cited by 223
Self-citationOkamoto, S., Thieme, A., Allmann, J., D’Alessandria, C., Maurer, T., Retz, M., Tauber, R., Heck, M. M., Wester, H.-J., Tamaki, N., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178483 · Cited by 213
Self-citationRahbar, K., Schmidt, M., Heinzel, A., Eppard, E., Bode, A., Yordanova, A., Claesener, M., & Ahmadzadehfar, H. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.173757 · Cited by 213
Self-citationKabasakal, L., AbuQbeitah, M., Aygün, A., Yeyin, N., Ocak, M., Demirci, E., & Toklu, T. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3125-3 · Cited by 208
Self-citationNeuroendocrine differentiation of prostate cancer leads to PSMA suppression
Bakht, M. K., Derecichei, I., Li, Y., Ferraiuolo, R.-M., Dunning, M., Oh, S. W., Hussein, A., Youn, H., Stringer, K. F., Jeong, C. W., et al. (2019) · Endocrine-Related Cancer · doi:10.1530/erc-18-0226 · Cited by 187
Schuchardt, C., Zhang, J., Kulkarni, H. R., Chen, X., Müller, D., & Baum, R. P. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262713 · Cited by 187
Self-citationEmmett, L., Crumbaker, M., Ho, B., Willowson, K., Eu, P., Ratnayake, L., Epstein, R., Blanksby, A., Horvath, L., Guminski, A., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.09.014 · Cited by 185
Self-citationBräuer, A., Grubert, L. S., Roll, W., Schrader, A. J., Schäfers, M., Bögemann, M., & Rahbar, K. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3751-z · Cited by 173
Self-citationAhmadzadehfar, H., Wegen, S., Yordanova, A., Fimmers, R., Kürpig, S., Eppard, E., Wei, X., Schlenkhoff, C., Hauser, S., & Essler, M. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3716-2 · Cited by 170
Rahbar, K., Boegemann, M., Yordanova, A., Eveslage, M., Schäfers, M., Essler, M., & Ahmadzadehfar, H. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3848-4 · Cited by 158
Self-citationGrubmüller, B., Senn, D., Kramer, G., Baltzer, P., D’Andrea, D., Grubmüller, K. H., Mitterhauser, M., Eidherr, H., Haug, A. R., Wadsak, W., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4236-4 · Cited by 158
Jackson, P. A., Hofman, M. S., Hicks, R. J., Scalzo, M., & Violet, J. A. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.233411 · Cited by 147
Self-citationFerdinandus, J., Eppard, E., Gaertner, F. C., Kürpig, S., Fimmers, R., Yordanova, A., Hauser, S., Feldmann, G., Essler, M., & Ahmadzadehfar, H. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178228 · Cited by 139
Barber, T. W., Singh, A., Kulkarni, H., Niepsch, K., Billah, B., & Baum, R. P. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.216820 · Cited by 137
Self-citationAhmadzadehfar, H., Rahbar, K., Baum, R. P., Seifert, R., Kessel, K., Bögemann, M., Kulkarni, H., Zhang, J., Gerke, C., Fimmers, R., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04797-9 · Cited by 128
Self-citationScarpa, L., Buxbaum, S., Kendler, D., Fink, K., Bektić, J., Gruber, L. N., Decristoforo, C., Uprimny, C., Lukas, P. H., Horninger, W., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3609-9 · Cited by 126
Self-citationYadav, M. P., Ballal, S., Bal, C., Sahoo, R. K., Damle, N. A., Tripathi, M., & Seth, A. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002833 · Cited by 122
Taylor, A. T., Brandon, D. C., Palma, D. D., Blaufox, M. D., Durand, E., Erbaş, B., Grant, S. F., Hilson, A. J. W., & Morsing, A. (2018) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2018.02.010 · Cited by 112
Konijnenberg, M., Herrmann, K., Kobe, C., Verburg, F. A., Hindorf, C., Hustinx, R., & Laßmann, M. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05038-9 · Cited by 109
Self-citationSadaghiani, M. S., Sheikhbahaei, S., Werner, R. A., Pienta, K. J., Pomper, M. G., Sólnes, L. B., Gorin, M. A., Wang, N., & Rowe, S. P. (2021) · European Urology · doi:10.1016/j.eururo.2021.03.004 · Cited by 109
Khreish, F., Ghazal, Z., Marlowe, R. J., Rosar, F., Sabet, A., Maus, S., Linxweiler, J., Bartholomä, M. D., & Ezziddin, S. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05525-7 · Cited by 107
Self-citationPrivé, B. M., Peters, S. M. B., Muselaers, S., van Oort, I. M., Janssen, M. J. R., Sedelaar, J. P. M., Konijnenberg, M., Zámecnik, P., Uijen, M. J. M., Schilham, M. G. M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4298 · Cited by 103
Self-citationRathke, H. G., Kratochwil, C., Hohenberger, R., Giesel, F. L., Bruchertseifer, F., Flechsig, P., Morgenstern, A., Hein, M., Plinkert, P. K., Haberkorn, U., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4135-8 · Cited by 93
Self-citationAhmadzadehfar, H., Schlolaut, S., Fimmers, R., Yordanova, A., Hirzebruch, S., Schlenkhoff, C. D., Gaertner, F. C., Awang, Z. H., Hauser, S., & Essler, M. (2017) · Oncotarget · doi:10.18632/oncotarget.21600 · Cited by 90
Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
Yordanova, A., Linden, P., Hauser, S., Meisenheimer, M., Kürpig, S., Feldmann, G., Gaertner, F. C., Essler, M., & Ahmadzadehfar, H. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4222-x · Cited by 90
Peters, S. M. B., Privé, B. M., de Bakker, M., de Lange, F., Jentzen, W., Eek, A., Muselaers, C. H. J., Mehra, N., Witjes, J. A., Gotthardt, M., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05471-4 · Cited by 88
Self-citationHohberg, M., Eschner, W., Schmidt, M. C., Dietlein, M., Kobe, C., Fischer, T. H., Drzezga, A. E., & Wild, M. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-0942-0 · Cited by 85
Yadav, M. P., Ballal, S., Tripathi, M., Damle, N. A., Sahoo, R. K., Seth, A., & Bal, C. (2016) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000606 · Cited by 85
Kabasakal, L., Toklu, T., Yeyin, N., Demirci, E., Abuqbeitah, M., Ocak, M., Aygün, A., Karayel, E., Pehlivanoğlu, H., & Selçuk, N. A. (2017) · Molecular Imaging and Radionuclide Therapy · doi:10.4274/mirt.08760 · Cited by 85
Self-citationKessel, K., Seifert, R., Schäfers, M. A., Weckesser, M., Schlack, K., Boegemann, M., & Rahbar, K. (2019) · Theranostics · doi:10.7150/thno.35759 · Cited by 84
Self-citationRepeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq
Rathke, H. G., Giesel, F. L., Flechsig, P., Kopka, K., Mier, W., Hohenfellner, M., Haberkorn, U., & Kratochwil, C. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.194209 · Cited by 83
Self-citationPeters, S. M. B., Hofferber, R., Privé, B. M., de Bakker, M., Gotthardt, M., Janssen, M. J. R., de Lange, F., Muselaers, S., Mehra, N., Witjes, J. A., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05538-2 · Cited by 82
Self-citationAhmadzadehfar, H., Zimbelmann, S., Yordanova, A., Fimmers, R., Kürpig, S., Eppard, E., Gaertner, F. C., Wei, X. X., Hauser, S., & Essler, M. (2017) · Oncotarget · doi:10.18632/oncotarget.15698 · Cited by 75
Heinzel, A., Boghos, D., Mottaghy, F. M., Gaertner, F. C., Essler, M., von Mallek, D., & Ahmadzadehfar, H. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-4258-6 · Cited by 72
Self-citationHotta, M., Gafita, A., Czernin, J. G., & Calais, J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263441 · Cited by 70
Self-citationSuman, S., Parghane, R. V., Joshi, A., Prabhash, K., Bakshi, G., Talole, S. D., Banerjee, S., & Basu, S. K. (2019) · British Journal of Radiology · doi:10.1259/bjr.20190380 · Cited by 69
Rathke, H. G., Holland‐Letz, T., Mier, W., Flechsig, P., Mavriopoulou, E., Röhrich, M., Kopka, K., Hohenfellner, M., Giesel, F. L., Haberkorn, U., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.231431 · Cited by 68
Self-citationGafita, A., Fendler, W. P., Wang, H., Sandhu, S. K., Weber, M., Esfandiari, R., Calais, J., Rauscher, I., Rathke, H. G., Tauber, R., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.05.004 · Cited by 68
Self-citationModeling and Predicting Tumor Response in Radioligand Therapy
Kletting, P., Thieme, A., Eberhardt, N., Rinscheid, A., D’Alessandria, C., Allmann, J., Wester, H., Tauber, R., Beer, A. J., Glatting, G., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210377 · Cited by 67
Self-citationRasul, S., Hacker, M., Kretschmer‐Chott, E., Leisser, A., Grubmüller, B., Kramer, G., Shariat, S. F., Wadsak, W., Mitterhauser, M., Hartenbach, M., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04584-1 · Cited by 67
Rosar, F., Kochems, N., Bartholomä, M. D., Maus, S., Stemler, T., Linxweiler, J., Khreish, F., & Ezziddin, S. (2021) · Cancers · doi:10.3390/cancers13123095 · Cited by 66
Self-citationSatapathy, S., Mittal, B. R., Sood, A. K., Das, C. K., Mavuduru, R. S., Goyal, S., Shukla, J., & Singh, S. K. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05618-3 · Cited by 60
Maffey-Steffan, J., Scarpa, L., Svirydenka, A., Nilica, B., Mair, C., Buxbaum, S., Bektić, J., von Guggenberg, E., Uprimny, C., Horninger, W., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04583-2 · Cited by 60
Self-citationRosar, F., Schön, N., Bohnenberger, H., Bartholomä, M. D., Stemler, T., Maus, S., Khreish, F., Ezziddin, S., & Schaefer-Schuler, A. (2021) · EJNMMI Physics · doi:10.1186/s40658-021-00385-4 · Cited by 58
Self-citationSarnelli, A., Belli, M. L., Iorio, V. D., Mezzenga, E., Celli, M., Severi, S., Tardelli, E., Nicolini, S., Oboldi, D., Uccelli, L., et al. (2019) · Molecules · doi:10.3390/molecules24030621 · Cited by 57
Paganelli, G., Sarnelli, A., Severi, S., Sansovini, M., Belli, M. L., Monti, M., Foca, F., Celli, M., Nicolini, S., Tardelli, E., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04856-1 · Cited by 57
Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial
Kuo, P. H., Benson, T., Messmann, R., & Groaning, M. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263638 · Cited by 56
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Rinscheid, A., Kletting, P., Eiber, M., Beer, A. J., & Glatting, G. (2020) · EJNMMI Physics · doi:10.1186/s40658-020-00311-0 · Cited by 56
Self-citationGosewisch, A., Ilhan, H., Tattenberg, S., Mairani, A., Parodi, K., Brosch-Lenz, J., Kaiser, L., Gildehaus, F. J., Todica, A. S., Ziegler, S. I., et al. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0548-z · Cited by 53
Calais, J., Gafita, A., Eiber, M., Armstrong, W. R., Gartmann, J., Thin, P., Nguyen, K., Lok, V. M., Gosa, L., Grogan, T., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.261982 · Cited by 53
Self-citationGosewisch, A., Delker, A., Tattenberg, S., Ilhan, H., Todica, A. S., Brosch-Lenz, J., Kaiser, L., Brunegraf, A., Gildehaus, F. J., Ziegler, S. I., et al. (2018) · EJNMMI Research · doi:10.1186/s13550-018-0427-z · Cited by 51
Assessing Response to 177Lu-PSMA Radioligand Therapy Using Modified PSMA PET Progression Criteria
Michalski, K., Klein, C., Brüggemann, T., Meyer, P. T., Jilg, C. A., & Ruf, J. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.260836 · Cited by 50
Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy
Filß, C., Heinzel, A., Miiller, B., Vogg, A. T. J., Langen, K., & Mottaghy, F. M. (2018) · Nuklearmedizin - NuclearMedicine · doi:10.3413/nukmed-0937-17-10 · Cited by 49
Self-citationSadaghiani, M. S., Sheikhbahaei, S., Werner, R. A., Pienta, K. J., Pomper, M. G., Gorin, M. A., Sólnes, L. B., & Rowe, S. P. (2022) · The Prostate · doi:10.1002/pros.24325 · Cited by 48
Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis
Seifert, R., Kessel, K., Schlack, K., Weckesser, M., Bögemann, M., & Rahbar, K. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04703-3 · Cited by 46
Self-citationWang, J., Zang, J., Wang, H., Liu, Q., Li, F., Lin, Y., Huo, L., Jacobson, O., Niu, G., Fan, X., et al. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002575 · Cited by 45
Khurshid, Z., Ahmadzadehfar, H., Gaertner, F. C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26051 · Cited by 44
Khreish, F., Kochems, N., Rosar, F., Sabet, A., Ries, M., Maus, S., Saar, M., Bartholomä, M. D., & Ezziddin, S. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04828-5 · Cited by 44
Self-citationCalais, J., Czernin, J. G., Thin, P., Gartmann, J., Nguyen, K., Armstrong, W. R., Allen-Auerbach, M., Quon, A. S. W., Bahri, S., Gupta, P. K., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262543 · Cited by 43
Self-citationWidjaja, L., Werner, R. A., Roß, T. L., Bengel, F. M., & Derlin, T. (2021) · Cancers · doi:10.3390/cancers13122938 · Cited by 37
Kesavan, M., Turner, J. H., Meyrick, D. P., Yeo, S. E. K., CARDACI, G. T., & Lenzo, N. P. (2018) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2017.2403 · Cited by 36
McBean, R. S., O'Kane, B., Parsons, R., & Wong, D. (2019) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.12891 · Cited by 34
Derlin, T., Werner, R. A., Lafos, M., Henkenberens, C., von Klot, C. A. J., Sohns, J. M. S., Roß, T. L., & Bengel, F. M. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.241588 · Cited by 34
Feuerecker, B., Chantadisai, M., Allmann, A., Tauber, R., Allmann, J., Steinhelfer, L., Rauscher, I., Wurzer, A. J., Wester, H., Weber, W., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262671 · Cited by 34
Self-citationDerlin, T., Sohns, J. M. S., Schmuck, S., Henkenberens, C., von Klot, C. A. J., Roß, T. L., & Bengel, F. M. (2020) · The Prostate · doi:10.1002/pros.23974 · Cited by 33
Völter, F., Mittlmeier, L. M., Gosewisch, A., Brosch-Lenz, J., Gildehaus, F. J., Zacherl, M. J., Beyer, L., Stief, C. G., Holzgreve, A., Rübenthaler, J., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11030428 · Cited by 33
Mix, M. D., Renaud, T., Kind, F., Nemer, U., Yousefzadeh‐Nowshahr, E., Moalosi, T. C. G., Ormrane, A. M., Meyer, P. T., & Ruf, J. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262245 · Cited by 33
Mahajan, S., Grewal, R. K., Friedman, K. P., Schöder, H. M., & Pandit-Taskar, N. D. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101445 · Cited by 33
Acar, E., Özdoğan, Ö., Aksu, A., Derebek, E., Bekiş, R., & Kaya, G. Ç. (2019) · Annals of Nuclear Medicine · doi:10.1007/s12149-019-01376-3 · Cited by 32
Maffey-Steffan, J., Scarpa, L., Svirydenka, A., Nilica, B., Mair, C., Buxbaum, S., Bektić, J., von Guggenberg, E., Uprimny, C., Horninger, W., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04660-6 · Cited by 32
Self-citationHeidegger, I. M., Kesch, C. V., Kretschmer, A., Tsaur, I., Ceci, F., Valério, M., Tilki, D., Marra, G., Preißer, F., Fankhauser, C. D., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221081922 · Cited by 32
Self-citationAghdam, R. A., Amoui, M., Ghodsirad, M., Khoshbakht, S., Mofid, B., Kaghazchi, F., Tavakoli, M., Pirayesh, E., & Ahmadzadehfar, H. (2019) · World Journal of Nuclear Medicine · doi:10.4103/wjnm.wjnm_66_18 · Cited by 31
Kurth, J., Heuschkel, M., Tonn, A., Schildt, A., Hakenberg, O. W., Krause, B. J., & Schwarzenböck, S. M. (2021) · Cancers · doi:10.3390/cancers13153884 · Cited by 30
First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands
van Kalmthout, L. W. M., Braat, A. J. A. T., Lam, M. G. E. H., van Leeuwaarde, R. S., Krijger, G. C., Ververs, T. F., Mehra, N., Bins, A. D., Hunting, J. C. B., & de Keizer, B. (2019) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002561 · Cited by 29
Khawar, A., Eppard, E., Sinnes, J., Roesch, F., Ahmadzadehfar, H., Kürpig, S., Meisenheimer, M., Gaertner, F. C., Essler, M., & Bundschuh, R. A. (2018) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000002102 · Cited by 28
Brosch-Lenz, J., Uribe, C., Gosewisch, A., Kaiser, L., Todica, A. S., Ilhan, H., Gildehaus, F. J., Bartenstein, P., Rahmim, A., Celler, A. M., et al. (2021) · EJNMMI Physics · doi:10.1186/s40658-021-00369-4 · Cited by 27
Calais, J., & Czernin, J. G. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263159 · Cited by 27
Self-citationKamaldeep, Wanage, G., Sahu, S., Maletha, P., Adnan, A., Suman, S., Basu, S. K., Das, T., & Banerjee, S. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.3640 · Cited by 26
Barna, S., Haug, A. R., Hartenbach, M., Rasul, S., Grubmüller, B., Kramer, G., & Blaickner, M. (2020) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003157 · Cited by 26
Suman, S., Parghane, R. V., Joshi, A., Prabhash, K., Talole, S. D., & Basu, S. K. (2021) · The Prostate · doi:10.1002/pros.24219 · Cited by 26
Kind, F., Fassbender, T. F., Andrieux, G., Boerries, M., Meyer, P. T., & Ruf, J. (2021) · Cancers · doi:10.3390/cancers14010149 · Cited by 24
Tuncel, M., Telli, T., Tuncalı, M. Ç., & Karabulut, E. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-021-01593-9 · Cited by 23
Chatachot, K., Shiratori, S., Chaiwatanarat, T., & Khamwan, K. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-021-01659-8 · Cited by 23
Nautiyal, A., Jha, A. K., Mithun, S., & Rangarajan, V. (2022) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001535 · Cited by 21
Herrmann, K., Rahbar, K., Eiber, M., Krause, B. J., Laßmann, M., Jentzen, W., Blumenstein, L., Klein, P. J., Basque, J., & Kurth, J. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.6_suppl.097 · Cited by 20
Self-citationNuclear medicine theranostics comes of age
Herrmann, K., Krause, B. J., Hadaschik, B. A., Kunikowska, J., van Poppel, H., N'Dow, J. M., Sartor, O., & Oyen, W. J. G. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00540-4 · Cited by 17
Self-citationGupta, M., Choudhury, P. S., Rawal, S. K., Karthikeyan, G., Talwar, V., Dutta, K. D., & Singh, A. D. (2019) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-019-00624-8 · Cited by 13
Kesavan, M., Meyrick, D. P., Gallyamov, M., Turner, J. H., Yeo, S. E. K., CARDACI, G. T., & Lenzo, N. P. (2021) · Diagnostics · doi:10.3390/diagnostics11030515 · Cited by 9
Rasul, S., Wollenweber, T., Zisser, L., Kretschmer‐Chott, E., Grubmüller, B., Kramer, G., Shariat, S. F., Eidherr, H., Mitterhauser, M., Vraka, C., et al. (2021) · Cancers · doi:10.3390/cancers13102489 · Cited by 8
Mahmoudi, E., Pirayesh, E., Deevband, M. R., Amoui, M., Rad, M. G., & Ghorbani, M. (2021) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-021-00713-7 · Cited by 8
Götz, T., Lang, E. W., Prante, O., Cordes, M., Kuwert, T., Ritt, P., Ludwig, B., & Schmidkonz, C. (2020) · Nuklearmedizin - NuclearMedicine · doi:10.1055/a-1204-9932 · Cited by 5
Cited by
Imaging and therapy in prostate cancer using prostate specific membrane antigen radioligands
Naik, M., Khan, S. R., Lewington, V., Challapalli, A., Eccles, A., & Barwick, T. D. (2024) · British Journal of Radiology · doi:10.1093/bjr/tqae092 · Cited by 10
Metadata
- Authors
- Kratochwil, C., Fendler, W. P., Eiber, M., Hofman, M. S., Emmett, L., Calais, J., Osborne, J. R., Iravani, A., Koo, P., Lindenberg, L., Baum, R. P., Bozkurt, M. F., Delgado Bolton, R. C., Ezziddin, S., Forrer, F., Hicks, R. J., Hope, T. A., Kabasakal, L., Konijnenberg, M., Kopka, K., Lassmann, M., Mottaghy, F. M., Oyen, W. J. G., Rahbar, K., Schoder, H., Virgolini, I., Bodei, L., Fanti, S., Haberkorn, U., & Hermann, K.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2023-05-29
- Volume
- 50
- Issue
- 9
- Pages
- 2830-2845
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W4378640167
- Cited by
- 299
- References
- 113
- FWCI
- 44.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.